Gilead — Piv­otal Covid-19 study of remde­sivir ‘met its pri­ma­ry end­point,' is emer­gency au­tho­riza­tion next?

Gilead has de­clared a huge vic­to­ry in the war against Covid-19.

In a short state­ment, the big biotech said that the piv­otal, con­trolled study of remde­sivir at the Na­tion­al In­sti­tute of Al­ler­gy and In­fec­tious Dis­eases had met its pri­ma­ry end­point. This was one of the key clin­i­cal hur­dles set up by NI­AID chief An­tho­ny Fau­ci.

Gilead $GILD in­clud­ed no da­ta in their state­ment, but said that NI­AID is plan­ning to sketch out the pos­i­tive re­sults in an up­com­ing brief­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER